EMA APPROVAL OF DRUGS ON THE BASIS OF PIVOTAL NON-COMPARATIVE PHASE II TRIAL DATA

被引：0
|
作者：
Macaulay, R. [1 ]
机构：
[1] HERON Hlth, London, England
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.009
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A324 / A324
页数：1
相关论文
共 50 条
  • [41] An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J. T. Hartmann
    K. Oechsle
    J. Huober
    A. Jakob
    M. Azemar
    M. Horger
    L. Kanz
    C. Bokemeyer
    Investigational New Drugs, 2006, 24 : 249 - 253
  • [42] A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)
    Salani, Ritu
    McCormack, Mary
    Kim, Yong-Man
    Ghamande, Sharad
    Hall, Shaundra L.
    Lorusso, Domenica
    Barraclough, Lisa
    Gilbert, Lucy
    Ramirez, Adrian Guzman
    Lu, Chien-Hsing
    Sabatier, Renaud
    Colombo, Nicoletta
    Hu, Youyou
    Krishnan, Venkatesh
    Molinero, Luciana
    Feng, Yuning
    Kim, Nicole
    Castro, Marcela
    Lin, Yvonne G.
    Monk, Bradley J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1140 - 1148
  • [43] DEALING WITH NON-COMPARATIVE DATA: PROPOSED ALTERNATIVES AND CONSIDERATIONS TO CONDUCT INDIRECT TREATMENT COMPARISONS (ITCS)
    Le, Nouveau P.
    Gauthier, A.
    VALUE IN HEALTH, 2022, 25 (12) : S365 - S366
  • [44] Piperacillin tazobactam in the treatment of hospitalized patients with urinary tract infections: An open non-comparative and multicentered trial
    SifuentesOsornio, J
    Jakob, E
    Clara, J
    Durlach, R
    Dain, A
    RuizPalacios, GM
    Barkan, L
    Lamberghini, R
    JOURNAL OF CHEMOTHERAPY, 1996, 8 (02) : 122 - 129
  • [45] Non-comparative phase II study of bendamustine hydrochloride in patients with pretreated soft tissue sarcoma (German Sarcoma Group-AIO 001).
    Mayer, F.
    Schleicher, J.
    Huober, J.
    Meisinger, I.
    Pintoffl, J.
    Kaefer, G.
    Gruenwald, V.
    Burkart, C.
    Kanz, L.
    Hartmann, J. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 526S - 526S
  • [46] Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
    Malka, David
    Cervera, Pascale
    Foulon, Stephanie
    Trarbach, Tanja
    de la Fouchardiere, Christelle
    Boucher, Eveline
    Fartoux, Laetitia
    Faivre, Sandrine
    Blanc, Jean-Frederic
    Viret, Frederic
    Assenat, Eric
    Seufferlein, Thomas
    Herrmann, Thomas
    Grenier, Julien
    Hammel, Pascal
    Dollinger, Matthias
    Andre, Thierry
    Hahn, Philipp
    Heinemann, Volker
    Rousseau, Vanessa
    Ducreux, Michel
    Pignon, Jean-Pierre
    Wendum, Dominique
    Rosmorduc, Olivier
    Greten, Tim F.
    LANCET ONCOLOGY, 2014, 15 (08): : 819 - 828
  • [47] Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs
    Takehiro Hirai
    Asuka Suzuki
    Takao Yamori
    Masaaki Matsuura
    Investigational New Drugs, 2022, 40 : 142 - 150
  • [48] Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs
    Hirai, Takehiro
    Suzuki, Asuka
    Yamori, Takao
    Matsuura, Masaaki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 142 - 150
  • [49] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Yau, Thomas
    Crocenzi, Todd S.
    Kudo, Masatoshi
    Hsu, Chiun
    Kim, Tae-You
    Choo, Su-Pin
    Trojan, Jorg
    Welling, Theodore H., III
    Meyer, Tim
    Kang, Yoon-Koo
    Yeo, Winnie
    Chopra, Akhil
    Anderson, Jeffrey
    dela Cruz, Christine
    Lang, Lixin
    Neely, Jaclyn
    Tang, Hao
    Dastani, Homa B.
    Melero, Ignacio
    LANCET, 2017, 389 (10088): : 2492 - 2502
  • [50] Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial
    Kuhn, Annegret
    Haust, Merle
    Ruland, Vincent
    Weber, Ramona
    Verde, Pablo
    Felder, Gerd
    Ohmann, Christian
    Gensch, Kristina
    Ruzicka, Thomas
    RHEUMATOLOGY, 2010, 49 (07) : 1336 - 1345
12345